cilostazol has been researched along with Scleroderma, Systemic in 1 studies
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol is a selective inhibitor of phosphodiesterase-III with antiplatelet, antithrombotic and vasodilating properties." | 1.43 | Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients. ( Filaci, G; Indiveri, F; Negrini, S; Penza, E; Puppo, F; Rollando, D; Spanò, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Negrini, S | 1 |
| Spanò, F | 1 |
| Penza, E | 1 |
| Rollando, D | 1 |
| Indiveri, F | 1 |
| Filaci, G | 1 |
| Puppo, F | 1 |
1 other study available for cilostazol and Scleroderma, Systemic
| Article | Year |
|---|---|
Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients.
Topics: Adult; Aged; Cilostazol; Controlled Before-After Studies; Humans; Middle Aged; Raynaud Disease; Scle | 2016 |